O.V. Kovaleva1, D.N. Kushlinskiy2, A.N. Gratchev3, E.P. Shapiro4, A.S. Mochalova5, N.Yu. Sokolov6, N.E. Kushlinskii7

1,3,5–7 N.N. Blokhin National Medical Research Center for Oncology
of the Ministry of Health of the Russian Federation (Moscow, Russia)

2,4 Clinical Center of Oncology (Khabarovsk, Russia)

The emergence of immune checkpoint inhibitors, mainly including monoclonal antibodies to PD-1/PD-L1 and CTLA-4 have shaped the therapeutic landscape of several types of malignancies. Recent advances in immunotherapy demonstrate good results: there is an increase in overall survival and objective response rates in patients with various tumor types. However, immunotherapy has not made significant progress in the therapy of ovarian cancer. That is why the search and study of new immune checkpoints is extremely urgent and promising.

The aim of this work is to analyze the current research on B7-H3 and B7-H4 proteins and their role in the pathogenesis of ovarian tumors.

Data are presented on the structure and classification of B7 family proteins, in particular B7-H3 and B7-H4, their role in the adaptive immune response, inhibition of proliferation, activation and cytokine production as well as in their interaction with intercellular matrix. Diverse functions of these proteins both in norm and in the development and progression of ovarian cancer are considered.

Evaluation of B7-H3 and B7-H4 expression levels may form the basis for the development of new therapeutic and diagnostic agents that can improve ovarian tumor therapy.

Kovaleva O.V., Kushlinskiy D.N., Gratchev A.N., Shapiro E.P., Mochalova A.S., Sokolov N.Yu., Kushlinskii N.E. Ovarian cancer and B7-H3 and B7-H4 ligands. Technologies of Living Systems. 2023. V. 20. № 3. Р. 36-47. DOI: https://doi.org/10.18127/j20700997-202303-05 (In Russian)

1. Antonia S.J., Extermann M., Flavell R.A. Immunologic nonresponsiveness to tumors. Crit. Rev. Oncog. 1998. V. 9. № 1. P. 35–41.
2. He C., Qiao H., Jiang H., Sun X. The inhibitory role of B7-H4 in antitumor immunity: association with cancer progression and survival. Clin. Dev. Immunol. 2011. P. 695834.
3. Igney F.H., Krammer P.H. Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukoc. Biol. 2002. V. 71. № 6. P. 907–920.
4. Scotta C., Soligo M., Camperio C., Piccolella E. FOXP3 induced by CD28/B7 interaction regulates CD25 and anergic phenotype in human CD4+CD25-T lymphocytes. J. Immunol. 2008. V. 181. № 2. P. 1025–1033.
5. Fridman W.H., Galon J., Pages F., Tartour E., Sautes-Fridman C., Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 2011. V. 71. № 17. P. 5601–5605.
6. Facciabene A., Peng X., Hagemann I.S., Balint K., Barchetti A., Wang L.P. et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011. V. 475. № 7355. P. 226–230.
7. Fauci J.M., Straughn J.M. Jr., Ferrone S., Buchsbaum D.J. A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecol. Oncol. 2012. V. 127. № 2. P. 420–425.
8. Ye Q., Liu J., Xie K. B7 Family Proteins in Cancer Progression: Immunological and Non-Immunological Functions. J. Cancer Treat. Diagn. 2019. V. 3. № 4. P. 1–6.
9. Yao S., Zhu Y., Zhu G., Augustine M., Zheng L., Goode D.J., Broadwater M., Ruff W., Flies S., Xu H., Flies D., Luo L., Wang S., Chen L. B7-h2 is a costimulatory ligand for CD28 in human. Immunity. 2011. V. 34. № 5. P. 729–740.
10. Zhuang X., Long E.O. CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7(+) Tumor Cells. Cancer Immunol. Res. 2019. V. 7. № 6. P. 939–951.
11. Chapoval A.I., Ni J., Lau J.S., Wilcox R.A., Flies D.B., Liu D., Dong H., Sica G.L., Zhu G., Tamada K., Chen L. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol. 2001. V. 2. № 3. P. 269–274.
12. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 2012. V. 12. № 4. P. 252–264.
13. Tringler B., Zhuo S., Pilkington G., Torkko K.C., Singh M., Lucia M.S., Heinz D.E., Papkoff J., Shroyer K.R. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin. Cancer Res. 2005. V. 11. № 5. P. 1842–1848.
14. Dangaj D., Lanitis E., Zhao A., Joshi S., Cheng Y., Sandaltzopoulos R., Ra H.J., Danet-Desnoyers G., Powell D.J. Jr., Scholler N. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res. 2013. V. 73. № 15. P. 4820–4829.
15. Fan M., Zhuang Q., Chen Y., Ding T., Yao H., Chen L., He X., Xu X. B7-H4 expression is correlated with tumor progression and clinical outcome in urothelial cell carcinoma. Int. J. Clin. Exp. Pathol. 2014. V. 7. № 10. P. 6768–6775.
16. Che F., Xie X., Wang L., Su Q., Jia F., Ye Y., Zang L., Wang J., Li H., Quan Y., You C., Yin J., Wang Z., Li G., Du Y., Wang L. B7-H6 expression is induced by lipopolysaccharide and facilitates cancer invasion and metastasis in human gliomas. Int. Immunopharmacol. 2018. V. 59. P. 318–327.
17. Fiegler N., Textor S., Arnold A., Rölle A., Oehme I., Breuhahn K., Moldenhauer G., Witzens-Harig M., Cerwenka A. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood. 2013. V. 122. № 5. P. 684–693.
18. Hashiguchi M., Kobori H., Ritprajak P., Kamimura Y., Kozono H., Azuma M. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc. Natl. Acad. Sci. U S A. 2008. V. 105. № 30. P. 10495–10500.
19. Leitner J., Klauser C., Pickl W.F., Stockl J., Majdic O., Bardet A.F. et al. B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction. Eur. J. Immunol. 2009. V. 39. № 7. P. 1754–1764.
20. Suh W.K., Gajewska B.U., Okada H., Gronski M.A., Bertram E.M., Dawicki W., Duncan G.S., Bukczynski J., Plyte S., Elia A., Wakeham A., Itie A., Chung S., Da Costa J., Arya S., Horan T., Campbell P., Gaida K., Ohashi P.S., Watts T.H., Yoshinaga S.K., Bray M.R., Jordana M., Mak T.W. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat. Immunol. 2003. V. 4. № 9. P. 899–906.
21. Luo L., Chapoval A.I., Flies D.B., Zhu G., Hirano F., Wang S., Lau J.S., Dong H., Tamada K., Flies A.S., Liu Y., Chen L. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J. Immunol. 2004. V. 173. № 9. P. 5445–5450.
22. Fukushima A., Sumi T., Fukuda K., Kumagai N., Nishida T., Yamazaki T., Akiba H., Okumura K., Yagita H., Ueno H. B7-H3 regulates the development of experimental allergic conjunctivitis in mice. Immunol. Lett. 2007. V. 113. № 1. P. 52–57.
23. Nagashima O., Harada N., Usui Y., Yamazaki T., Yagita H., Okumura K., Takahashi K., Akiba H. B7-H3 contributes to the development of pathogenic Th2 cells in a murine model of asthma. J. Immunol. 2008. V. 181. № 6. P. 4062–4071.
24. Wu C.P., Jiang J.T., Tan M., Zhu Y.B., Ji M., Xu K.F., Zhao J.M., Zhang G.B., Zhang X.G. Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J. Gastroenterol. 2006. V. 12. № 3. P. 457–459.
25. Zang X., Thompson R.H., Al-Ahmadie H.A., Serio A.M., Reuter V.E., Eastham J.A., Scardino P.T., Sharma P., Allison J.P. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc. Natl. Acad. Sci. U S A. 2007. V. 104. № 49. P. 19458–19463.
26. Boorjian S.A., Sheinin Y., Crispen P.L., Farmer S.A., Lohse C.M., Kuntz S.M., Leibovich B.C., Kwon E.D., Frank I. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin. Cancer Res. 2008. V. 14. № 15. P. 4800–4808.
27. Crispen P.L., Sheinin Y., Roth T.J., Lohse C.M., Kuntz S.M., Frigola X., Thompson R.H., Boorjian S.A., Dong H., Leibovich B.C., Blute M.L., Kwon E.D. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin. Cancer Res. 2008. V. 14. № 16. P. 5150–5157.
28. Loos M., Hedderich D.M., Ottenhausen M., Giese N.A., Laschinger M., Esposito I., Kleeff J., Friess H. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer. 2009. V. 9. P. 463.
29. Jiang J., Zhu Y., Wu C., Shen Y., Wei W., Chen L., Zheng X., Sun J., Lu B., Zhang X. Tumor expression of B7–H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol. Immunother. 2010. V. 59. № 11. P. 1707–1714.
30. Sun J., Chen L.J., Zhang G.B., Jiang J.T., Zhu M., Tan Y., Wang H.T., Lu B.F., Zhang X.G. Clinical significance and regulation of the costimulatory molecule B7–H3 in human colorectal carcinoma. Cancer Immunol. Immunother. 2010. V. 59. № 8. P. 1163–1171.
31. Zang X., Sullivan P.S., Soslow R.A., Waitz R., Reuter V.E., Wilton A., Thaler H.T., Arul M., Slovin S.F., Wei J., Spriggs D.R., Dupont J., Allison J.P. Tumor associated endothelial expression of B7–H3 predicts survival in ovarian carcinomas. Mod. Pathol. 2010. V. 23. № 8. P. 1104–1112.
32. Roth T.J., Sheinin Y., Lohse C.M., Kuntz S.M., Frigola X., Inman B.A., Krambeck A.E., McKenney M.E., Karnes R.J., Blute M.L., Cheville J.C., Sebo T.J., Kwon E.D. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007. V. 67. № 16. P. 7893–7900.
33. Crispen P.L., Sheinin Y., Roth T.J., Lohse C.M., Kuntz S.M., Frigola X., Thompson R.H., Boorjian S.A., Dong H., Leibovich B.C., Blute M.L., Kwon E.D. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin. Cancer Res. 2008. V. 14. № 16. P. 5150–5157.
34. Gregorio A., Corrias M.V., Castriconi R., Dondero A., Mosconi M., Gambini C., Moretta A., Moretta L., Bottino C. Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule. Histopathology. 2008. V. 53. № 1. P. 73–80.
35. Yamato I., Sho M., Nomi T., Akahori T., Shimada K., Hotta K., Kanehiro H., Konishi N., Yagita H., Nakajima Y. Clinical importance of B7-H3 expression in human pancreatic cancer. Br. J. Cancer. 2009. V. 101. № 10. P. 1709–1716.
36. Xu H., Cheung I.Y., Guo H.F., Cheung N.K. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 2009. V. 69. № 15. P. 6275–6281.
37. Chen Y.W., Tekle C., Fodstad O. The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Curr. Cancer Drug Targets. 2008. V. 8. № 5. P. 404–413.
38. Liu H., Tekle C., Chen Y.W., Kristian A., Zhao Y., Zhou M., Liu Z., Ding Y., Wang B., Mælandsmo G.M., Nesland J.M., Fodstad O., Tan M. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol. Cancer Ther. 2011. V. 10. № 6. P. 960–971.
39. Sica G.L., Choi I.H., Zhu G., Tamada K., Wang S.D., Tamura H., Chapoval A.I., Flies D.B., Bajorath J., Chen L. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003. V. 18. № 6. P. 849–861.
40. Zang X., Loke P., Kim J., Murphy K., Waitz R., Allison J.P. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc. Natl. Acad. Sci. U S A. 2003. V. 100. № 18. P. 10388–10392.
41. Choi I.H., Zhu G., Sica G.L., Strome S.E., Cheville J.C., Lau J.S., Zhu Y., Flies D.B., Tamada K., Chen L. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 2003. V. 171. № 9. P. 4650–4654.
42. Carreno B.M., Collins M. BTLA: a new inhibitory receptor with a B7-like ligand. Trends Immunol. 2003. V. 24. № 10. P. 524–527.
43. Prasad D.V., Richards S., Mai X.M., Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity. 2003. V. 18. № 6. P. 863–873.
44. Salceda S., Tang T., Kmet M., Munteanu A., Ghosh M., Macina R., Liu W., Pilkington G., Papkoff J. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp. Cell Res. 2005. V. 306. № 1.
    P. 128–141.
45. Tringler B., Zhuo S., Pilkington G., Torkko K.C., Singh M., Lucia M.S., Heinz D.E., Papkoff J., Shroyer K.R. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin. Cancer Res. 2005. V. 11. № 5. P. 1842–1848.
46. Krambeck A.E., Thompson R.H., Dong H., Lohse C.M., Park E.S., Kuntz S.M., Leibovich B.C., Blute M.L., Cheville J.C., Kwon E.D. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl. Acad. Sci. U S A. 2006. V. 103. № 27. P. 10391–10396.
47. Jiang J., Zhu Y., Wu C., Shen Y., Wei W., Chen L., Zheng X., Sun J., Lu B., Zhang X. Tumor expression of B7–H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol. Immunother. 2010. V. 59. № 11. P. 1707–1714.
48. Cheng L., Jiang J., Gao R., Wei S., Nan F., Li S., Kong B. B7-H4 expression promotes tumorigenesis in ovarian cancer. Int. J. Gynecol. Cancer. 2009. V. 19. № 9. P. 1481–1486.
49. Simon I., Katsaros D., Rigault de la Longrais I., Massobrio M., Scorilas A., Kim N.W., Sarno M.J., Wolfert R.L., Diamandis E.P. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol. Oncol. 2007. V. 106. № 2. P. 334–341.
50. Kryczek I., Zou L., Rodriguez P., Zhu G., Wei S., Mottram P., Brumlik M., Cheng P., Curiel T., Myers L., Lackner A., Alvarez X., Ochoa A., Chen L., Zou W. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 2006. V. 203. № 4. P. 871–881.
51. Zheng Y., Katsaros D., Shan S.J., de la Longrais I.R., Porpiglia M., Scorilas A., Kim N.W., Wolfert R.L., Simon I., Li L., Feng Z., Diamandis E.P. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin. Cancer Res. 2007. V. 13. № 23. P. 6984–6992.
52. Oikonomopoulou K., Li L., Zheng Y., Simon I., Wolfert R.L., Valik D., Nekulova M., Simickova M., Frgala T., Diamandis EP. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br. J. Cancer. 2008. V. 99. № 7. P. 1103–1113.